


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4817658/publications.pdf Version: 2024-02-01



YUKIO

#	Article	IF	CITATIONS
1	The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecologic Oncology, 2006, 103, 1083-1090.	1.4	305
2	Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinumâ€sensitive epithelial ovarian carcinoma. Cancer, 2006, 106, 1933-1939.	4.1	287
3	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	1.6	66
4	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 262-266.	1.4	43
5	Risk factors for financial toxicity in patients with gynecologic cancer. American Journal of Obstetrics and Gynecology, 2022, 226, 817.e1-817.e9.	1.3	20
6	Indications for and complications of transfusion and the management of gynecologic malignancies. Gynecologic Oncology, 2017, 146, 416-426.	1.4	18
7	Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. Gynecologic Oncology, 2014, 132, 299-302.	1.4	14
8	Schauta radical vaginal hysterectomy. Gynecologic Oncology, 2007, 104, 20-24.	1.4	13
9	Radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy for early-stage cervical cancer in patients who desire to preserve fertility. Gynecologic Oncology, 2007, 104, 50-55.	1.4	13
10	Electronic patient-reported symptom monitoring in patients recovering from ambulatory minimally invasive gynecologic surgery: A prospective pilot study. Gynecologic Oncology, 2020, 159, 187-194.	1.4	12
11	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. International Journal of Gynecological Cancer, 2022, 32, 159-164.	2.5	10
12	Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecologic Oncology, 2021, 163, 294-298.	1.4	9
13	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. Gynecologic Oncology, 2022, 165, 239-247.	1.4	9
14	Diaphragm hernia after debulking surgery in patients with ovarian cancer. Gynecologic Oncology Reports, 2021, 36, 100759.	0.6	2
15	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. JCO Clinical Cancer Informatics, 2022, 6, e2100154.	2.1	2
16	Fertility-sparing surgery in gynecologic oncology. Expert Review of Obstetrics and Gynecology, 2008, 3, 211-221.	0.4	1
17	OUP accepted manuscript. Oncologist, 2022, , .	3.7	0